Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Items 101–200 of 1,003
Montessori education: a review of the evidence base
Marshall, C. (2017) · npj Science of Learning · doi:10.1038/s41539-017-0012-7 · Cited by 195
A Self-Destructive Nanosweeper That Captures and Clears Amyloid β-Peptides
Luo, Q., Lin, Y.-X., Yang, P.-P., Wang, Y., Qi, G.-B., Qiao, Z.-Y., Li, B.-N., Zhang, K., Zhang, J.-P., Wang, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04255-z · Cited by 191
Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
Geifman, N., Brinton, R. D., Kennedy, R. E., Schneider, L. S., & Butte, A. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0237-y · Cited by 191
“As of 2008, at least 172 drug development failures in AD therapeutics were identified [5, 6].”
BackgroundCummings, J. L., Zhong, K., Kinney, J. W., Heaney, C., Moll-Tudla, J., Joshi, A., Pontecorvo, M., Devous, M., Tang, A., & Bena, J. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0173-2 · Cited by 190
“All attempts to develop disease-modifying treatments for AD have failed [4].”
BackgroundSelf-citationWang, C.-Y., Xu, Y., Wang, X., Guo, C., Wang, T., & Wang, Z.-Y. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7440 · Cited by 190
“Clinical trials targeting anti-A b therapies failed to inhibit the progression of AD patients’ cognitive decline (13), leading the field to explore novel targets for therapeutic intervention (9, 10).”
New Approaches for the Treatment of Alzheimer’s Disease
Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.034 · Cited by 189
“gov.(27) Only one of these, memantine (7), successfully completed clinical trials and was approved by the FDA; this represents a success rate of just 0.”
BackgroundGasiorowska, A., Wydrych, M., Drapich, P., Zadrozny, M., Steczkowska, M., Niewiadomski, W., & Niewiadomska, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.654931 · Cited by 184
“…approved since the approval of memantine (an NMDAR antagonist) in 2003 following the approval in 2001 of galantamine, the last of four acetylcholine esterase inhibitors (AChEIs) (the others being tacrine, donepezil, rivastigmine) recommended in the treatment of dementia (Cummings et al., 2014).”
BackgroundSalameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
Understanding the Amyloid Hypothesis in Alzheimer’s Disease
Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180802 · Cited by 187
“Thus, as underlined by the therapeutic failure of over 400 candidate drugs in the last two decades [4, 5], effective treatments are also missing.”
Technological Peer Pressure and Product Disclosure
Cao, S. S., Ma, G., Tucker, J. W., & Wan, C. (2018) · The Accounting Review · doi:10.2308/accr-52056 · Cited by 185
Singh, S. K., Srivastav, S., Yadav, A. K., Srikrishna, S., & Perry, G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7361613 · Cited by 186
“In contrast numerous drug targets have “cured” these mouse models while having no benefit in clinical trials of AD patients [131].”
BackgroundWu, L., Zhang, X., & Zhao, L. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.2262-17.2018 · Cited by 185
“The growing number of AD cases, along with continuous failures in AD drug development (Cummings et al., 2014), underscores the urgent need for advancement in the area of AD therapy.”
BackgroundMolinuevo, J. L., Gramunt, N., Gispert, J. D., Fauria, K., Esteller, M., Minguillon, C., Sánchez‐Benavides, G., Huesa, G., Morán, S., Dal‐Ré, R., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.02.003 · Cited by 182
“In addition, disease-modifying pharmacological interventions on both mild moderate and late-stage AD persons have yet to produce significant clinical benefits [48].”
BackgroundAxonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders
Salvadores, N., Sanhueza, M., Manque, P., & Court, F. A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00451 · Cited by 182
“However, the overall outcomes have been dramatic, with a 99.6% failure rate for approval (Cummings et al., 2014).”
BackgroundInfluentialJavaid, F. Z., Brenton, J., Guo, L., & Cordeiro, M. F. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00055 · Cited by 178
“Amyloid-β(1-42) alters structure and function of retinal pigmented epithelial cells.”
BackgroundSimulation Studies of Amyloidogenic Polypeptides and Their Aggregates
Ilie, I. M., & Caflisch, A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00731 · Cited by 178
Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology
Hampel, H., (APMI), F. T. A. P. M. I., Toschi, N., Babiloni, C., Baldacci, F., Black, K. L., Bokde, A. L. W., Bun, R. S., Cacciola, F., Cavedo, E., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179932 · Cited by 176
Hodes, R. J., & Buckholtz, N. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1135132 · Cited by 174
Cummings, J., Ritter, A., & Zhong, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179901 · Cited by 176
“Placebo decline determines drug-placebo difference Successful DMTs will slow the course of decline in AD.”
BackgroundInfluentialSelf-citationThe present and future of pharmacotherapy of Alzheimer's disease: a comprehensive review
Anand, A., Patience, A. A., Sharma, N., & Khurana, N. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.043 · Cited by 174
Synaptic pathology: A shared mechanism in neurological disease
Henstridge, C. M., Pickett, E., & Spires-Jones, T. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.005 · Cited by 174
“failed to reach their primary clinical endpoints [216], highlighting the difficulty of translational medicine in the field of neurodegenerative diseases.”
The Amyloid Phenomenon and Its Significance in Biology and Medicine
Dobson, C. M., Knowles, T. P. J., & Vendruscolo, M. (2020) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033878 · Cited by 173
“Early drug discovery efforts, at least partly for this reason, have led to very disappointing clinical trials, in particular those targeted at neurodegenerative conditions (Cummings et al. 2014, 2018).”
BackgroundAAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease
Rosenberg, J. B., Kaplitt, M. G., De, B. P., Chen, A., Flagiello, T., Salami, C., Pey, E., Zhao, L., Ricart Arbona, R. J., Monette, S., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.231 · Cited by 176
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.(3,4) The major risk factor for AD is inheritance of the E4 allele of apolipoprotein E (APOE).”
BackgroundMethodGallaway, P., Miyake, H., Buchowski, M., Shimada, M., Yoshitake, Y., Kim, A., & Hongu, N. (2017) · Brain Sciences · doi:10.3390/brainsci7020022 · Cited by 169
“Perhaps the most alarming aspect of the increase in dementia cases, is that there are currently no cures or new effective therapies [8].”
BackgroundThe genes associated with early-onset Alzheimer’s disease
Dai, M.-H., Zheng, H., Zeng, L.-D., & Zhang, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.23738 · Cited by 167
“We urgently need to development of effective treatment strategies to prevent, delay the onset, slow the progression, or improve the symptoms of AD [3].”
BackgroundBerman, M. H., Halper, J. P., Nichols, T. W., H, J., Lundy, A., & Huang, J. H. (2017) · Journal of Neurology and Neuroscience · doi:10.21767/2171-6625.1000176 · Cited by 168
“Antibody therapy of Tau and Amyloid beta, vaccines and other methods to decrease Tau and or Amyloid have not been successful after considerable pharmaceutical and biotech efforts [2].”
BackgroundGenetic correlations between Alzheimer’s disease and gut microbiome genera
Cammann, D., Lu, Y., Cummings, M. J., Zhang, M. L., Cue, J. M., Do, J., Ebersole, J., Chen, X., Oh, E. C., Cummings, J. L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-31730-5 · Cited by 163
Self-citationTarget Enzyme in Alzheimer’s Disease: Acetylcholinesterase Inhibitors
Saxena, M., & Dubey, R. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190128125912 · Cited by 162
Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer’s Disease
Sonawane, S. K., Ahmad, A., & Chinnathambi, S. (2019) · ACS Omega · doi:10.1021/acsomega.9b01411 · Cited by 166
“The research has yielded therapeutics from di ff erent classes like small molecules, natural compounds, peptide inhibitors, etc. 16,17 Along with these classes of therapeutics, considerable research is being done in the fi eld of nanoparticles (NPs) with respect to protein aggregation.”
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Eid, A., Mhatre, I., & Richardson, J. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.005 · Cited by 164
Sohn, D., Shpanskaya, K., Lucas, J. E., Petrella, J. R., Saykin, A. J., Tanzi, R. E., Samatova, N. F., & Doraiswamy, P. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-25377-w · Cited by 161
Benzofuran and Indole: Promising Scaffolds for Drug Development in Alzheimer's Disease
Goyal, D., Kaur, A., & Goyal, B. (2018) · ChemMedChem · doi:10.1002/cmdc.201800156 · Cited by 168
Chandrasekaran, A., Avci, H. X., Leist, M., Kobolák, J., & Dinnyés, A. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00215 · Cited by 153
“Most strikingly, various drugs that showed promise in an animal model have failed in human trials (Cavanaugh et al., 2014; Cummings et al., 2014).”
BackgroundCheng, W., & Ng, C. A. (2019) · Environmental Science & Technology · doi:10.1021/acs.est.9b04833 · Cited by 152
Stem cell therapy for Alzheimer's disease
Liu, X.-Y., Yang, L.-P., & Zhao, L. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i8.787 · Cited by 144
The Role of Biomarkers in Alzheimer’s Disease Drug Development
Cummings, J. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_2 · Cited by 148
Self-citationArora, S., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00461 · Cited by 149
Recent progress in multifunctional metal chelators as potential drugs for Alzheimer's disease
Santos, M. A., Chand, K., & Chaves, S. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.04.013 · Cited by 159
Limbocker, R., Chia, S., Ruggeri, F. S., Perni, M., Cascella, R., Heller, G. T., Meisl, G., Mannini, B., Habchi, J., Michaels, T. C. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07699-5 · Cited by 161
Alzheimer's disease: The right drug, the right time
Golde, T. E., DeKosky, S. T., & Galasko, D. (2018) · Science · doi:10.1126/science.aau0437 · Cited by 147
Cui, Y., Ma, S., Zhang, C., Cao, W., Liu, M., Li, D., Lv, P., Xing, Q., Qu, R., Yao, N., et al. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.12.021 · Cited by 163
Joshi, A. U., Saw, N. L., Shamloo, M., & Mochly-Rosen, D. (2018) · Oncotarget · doi:10.18632/oncotarget.23640 · Cited by 145
“Although the contribution of Aβ oligomers to AD pathogenesis is still unclear, suppressing Aβ-induced cytotoxicity has been the focus of much of the drug development effort for AD [59].”
BackgroundOpportunities and challenges in modeling human brain disorders in transgenic primates
Jennings, C. G. B., Landman, R., Zhou, Y., Sharma, J., Hyman, J. B., Movshon, J. A., Qiu, Z., Roberts, A., Roe, A. W., Wang, X., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4362 · Cited by 151
Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease
Kang, S., Lee, Y.-H., & Lee, J. E. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.3.479 · Cited by 143
“6% of drug candidates targeting amyloid pathways, such as beta secretase inhibitors, gamma secretase inhibitors, and Aβ itself, have failed.(18) In addition, a weak correlation between Aβ deposition and cognitive decline have been reported.”
BackgroundAdvances in Alzheimer’s Diagnosis and Therapy: The Implications of Nanotechnology
Hajipour, M. J., Santoso, M. R., Rezaee, F., Aghaverdi, H., Mahmoudi, M., & Perry, G. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.06.002 · Cited by 143
Mechanisms of protein toxicity in neurodegenerative diseases
Chung, C. G., Lee, H., & Lee, S. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2854-4 · Cited by 142
Santos, R., Vadodaria, K. C., Jaeger, B. N., Mei, A., Lefcochilos-Fogelquist, S., Mendes, A. P. D., Erikson, G., Shokhirev, M., Randolph-Moore, L., Fredlender, C., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.05.011 · Cited by 141
Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer’s Disease
Rossi, M., Freschi, M., Nascente, L. D. C., Salerno, A., Teixeira, S. D. M. V., Nachon, F., Chantegreil, F., Soukup, O., Prchal, L., Malaguti, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00048 · Cited by 147
Fang, J., Zhang, P., Wang, Q., Chiang, C.-W., Zhou, Y., Hou, Y., Xu, J., Chen, R., Zhang, B., Lewis, S. J., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00951-z · Cited by 140
Self-citationObjective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration
Thomas, K. R., Bangen, K. J., Weigand, A. J., Edmonds, E. C., Wong, C. G., Cooper, S., Delano‐Wood, L., Bondi, M. W., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000008838 · Cited by 147
Gamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?
Bursavich, M. G., Harrison, B. A., & Blain, J.-F. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01960 · Cited by 137
CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics
Bhardwaj, S., Kesari, K. K., Rachamalla, M., Mani, S., Ashraf, G. M., Jha, S. K., Kumar, P., Ambasta, R. K., Dureja, H., Devkota, H. P., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.07.001 · Cited by 158
“The constantly increasing numbers of affected patients leads to projections of approximately 14 million in the USA by 2050 [11].”
BackgroundIs Target-Based Drug Discovery Efficient? Discovery and “Off-Target” Mechanisms of All Drugs
Sadri, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01737 · Cited by 163
An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer’s disease
Ghosh, A., Comerota, M. M., Wan, D., Chen, F., Propson, N. E., Hwang, S. H., Hammock, B. D., & Zheng, H. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb1206 · Cited by 136
DNA polymerase β deficiency leads to neurodegeneration and exacerbates Alzheimer disease phenotypes
Sykora, P., Misiak, M., Wang, Y., Ghosh, S., Leandro, G. S., Liu, D., Tian, J., Baptiste, B. A., Cong, W.-N., Brenerman, B. M., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1356 · Cited by 136
“A recent assessment of Alzheimer’s drugs in development has reported a drug failure rate of over 99% (1).”
BackgroundProtective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
Human neural stem cell transplantation improves cognition in a murine model of Alzheimer’s disease
McGinley, L. M., Kashlan, O. N., Bruno, E. S., Chen, K. S., Hayes, J. M., Kashlan, S. R., Raykin, J., Johe, K., Murphy, G. G., & Feldman, E. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-33017-6 · Cited by 133
Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer’s disease
Xiong, F., Ge, W., & Ma, C. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.10.006 · Cited by 133
“Despite yielding promising effects in mouse models, these attempts have failed to show substantial efficacy in clinical trials [7,8].”
BackgroundLundin, A., Delsing, L., Clausen, M., Ricchiuto, P., Sanchez, J., Sabirsh, A., Ding, M., Synnergren, J., Zetterberg, H., Brolén, G., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.021 · Cited by 131
“Historically, high failure rates of drug candidates in clinical trials for neurological diseases, such as Alzheimer’s disease (AD) (Cummings et al., 2014), in combinationwith a recognized possible role of astrocytes in AD (Yu et al., 2014), cre- 1030 Stem Cell Reports j Vol. 10 j 1030–1045 j March…”
BackgroundAPOE-amyloid interaction: Therapeutic targets
Wisniewski, T., & Drummond, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104784 · Cited by 131
“6% of AD targeting clinical trials (Cummings et al., 2014; Banik et al., 2015; Schneider et al., 2014).”
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129
“AD are acetylcholine esterase inhibitors, including tacrine (first approved treatment, withdrawn soon after because of reports of liver toxicity), donepezil (also approved for severe AD), rivastigmine (also approved for severe AD), and galantamine [1, 2].”
BackgroundInfluentialMoss, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103438 · Cited by 146
Therapeutic Potential of TNF-α Inhibition for Alzheimer’s Disease Prevention
Torres-Acosta, N., O’Keefe, J. H., O’Keefe, E. L., Isaacson, R., & Small, G. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200711 · Cited by 126
“6% failure rate—the worst for any therapeutic area according to the US Food and Drug data [1, 2].”
BackgroundThe mitochondrial ATP synthase is a shared drug target for aging and dementia
Goldberg, J., Currais, A. J. M., Prior, M., Fischer, W. H., Chiruta, C., Ratliff, E. P., Daugherty, D., Dargusch, R., Finley, K. D., Esparza‐Moltó, P. B., et al. (2018) · Aging Cell · doi:10.1111/acel.12715 · Cited by 134
BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
Maia, M. A., & Sousa, E. (2019) · Pharmaceuticals · doi:10.3390/ph12010041 · Cited by 126
“These include four acetylcholinesterase inhibitors (AChEi) - tacrine (approved in 1993), donepezil (approved in 1996), rivastigmine (1998), and galantamine (approved in 2001) [9].”
BackgroundInfluentialRhesus macaques as a tractable physiological model of human ageing
Chiou, K. L., Montague, M. J., Goldman, E. A., Watowich, M. M., Sams, S. N., Song, J., Horvath, J. E., Sterner, K. N., Ruiz-Lambides, A. V., Martínez, M. I., et al. (2020) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2019.0612 · Cited by 139
“In fact, therapeutics developed based on preclinical studies of short-lived laboratory organisms encounter a high failure rate in clinical trials, both in the ageing domain [2] and otherwise [3].”
BackgroundLeptin Dysfunction and Alzheimer’s Disease: Evidence from Cellular, Animal, and Human Studies
McGuire, M. J., & Ishii, M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0282-7 · Cited by 125
“Despite extensive efforts, recent AD clinical trials have been largely disappointing with no new AD drug approved by the US Food and Drug Administrations (FDA) since memantine in 2003 (Cummings et al. 2014).”
Neurohealth Properties ofHericium erinaceusMycelia Enriched with Erinacines
Li, I.-C., Lee, L., Tzeng, T.-T., Chen, W.-P., Chen, Y., Shiao, Y., & Chen, C. (2018) · Behavioural Neurology · doi:10.1155/2018/5802634 · Cited by 162
“Similarly, despite one new drug out of 244 compounds tested in 413 Alzheimer’s disease clinical trials between 2002 and 2012 being approved for use, it cannot stop Alzheimer’s from progressing [6].”
BackgroundNeurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Alzheimer's disease failed clinical trials
Asher, S., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120861 · Cited by 124
Giampietro, R., Spinelli, F., Contino, M., & Colabufo, N. A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00841 · Cited by 123
Genome instability in Alzheimer disease
Hou, Y., Song, H., Croteau, D. L., Akbari, M., & Bohr, V. A. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.04.005 · Cited by 120
“The notion that Aβ plaques might not be causative of AD is further supported by the inefficacy of drugs affecting this pathway (Cummings et al., 2014; Godyn et al., 2016; Jia et al., 2014).”
BackgroundDisease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
TLR4 is a link between diabetes and Alzheimer’s disease
Huang, N., Jin, H. D., Zhou, S., Shi, J., & Jin, F. J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.08.047 · Cited by 126
Yi, B., Sahn, J. J., Ardestani, P. M., Evans, A. K., Scott, L. L., Chan, J. Z., Iyer, S., Crisp, A., Zuniga, G., Pierce, J. T., et al. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.13917 · Cited by 116
“However, these medications do not alter pathology underlying the disease (Cummings et al. 2014), and there remains an unmet need for therapeutic approaches to treat AD.”
The wonderland of neuronal nicotinic acetylcholine receptors
Bertrand, D., & Terry, A. V. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.008 · Cited by 125
Animal-assisted therapy in adults: A systematic review
Charry-Sánchez, J. D., Pradilla, I., & Talero-Gutiérrez, C. (2018) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2018.06.011 · Cited by 116
Alghazwi, M., Smid, S., Musgrave, I., & Zhang, W. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.01.010 · Cited by 115
“aspartate (NMDA) receptor (memantine) have been approved to reduce some symptoms experienced by AD sufferers (Cummings et al., 2014).”
Are the neuroprotective effects of exercise training systemically mediated?
Tari, A. R., Norevik, C. S., Scrimgeour, N. R., Kobro-Flatmoen, A., Storm-Mathisen, J., Bergersen, L. H., Wrann, C. D., Selbæk, G., Kivipelto, M., Moreira, J. B. N., et al. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.02.003 · Cited by 115
“Thus, the need for optimized prevention, diagnostics and treatment of AD and other forms of dementia is obvious.(5) A growing body of evidence suggests that brain health is closely”
BackgroundSun, Y., Sommerville, N. R., Liu, J. Y. H., Ngan, M. P., Poon, D., Ponomarev, E. D., Lu, Z., Kung, J. S. C., & Rudd, J. A. (2020) · The Journal of Physiology · doi:10.1113/jp279919 · Cited by 115
Xu, J., Mao, C., Hou, Y., Luo, Y., Binder, J. L., Zhou, Y., Bekris, L. M., Shin, J., Hu, M., Wang, F., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111717 · Cited by 115
Self-citationZhang, L., Zhang, S., Maezawa, I., Trushin, S., Minhas, P., Pinto, M., Jin, L.-W., Prasain, K., Nguyen, T. D. T., Yamazaki, Y., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.03.009 · Cited by 113
“However, to date, all clinical trials designed to low levels of Aβ by either blocking activity ofβ or γ secretases, preventing Aβ aggregation, or promoting Aβ clearance by immunotherapy have failed (Cummings et al., 2014) emphasizing an urgent need to find new therapies for AD.”
Acoustic enhancement of sleep slow oscillations in mild cognitive impairment
Papalambros, N. A., Weintraub, S., Chen, T., Grimaldi, D., Santostasi, G., Paller, K. A., Zee, P. C., & Malkani, R. G. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.796 · Cited by 113
Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges
Pais, M. V., Martinez, L. D., Ribeiro, O. G., Loureiro, J. C., Fernandez, R., Valiengo, L. D. C. L., Canineu, P. R., Stella, F., Talib, L. L., Radanovic, M., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0735 · Cited by 144
Hsu, C., Pan, Y., Zheng, Y., Lo, R. Y., & Yang, F. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14333 · Cited by 128
“3,4 A method of manipulating the microglial phenotype could po - tentially be an effective treatment for multiple human neurode - generative diseases.”
MethodLi, Q., Yang, X., Xu, J., Guo, Y., He, X., Hu, H., Lyu, T., Marra, D., Miller, A., Smith, G., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12967 · Cited by 113
Evidence for widespread, severe brain copper deficiency in Alzheimer's dementia
Xu, J., Church, S. J., Patassini, S., Begley, P., Waldvogel, H. J., Curtis, M. A., Faull, R. L. M., Unwin, R. D., & Cooper, G. J. S. (2017) · Metallomics · doi:10.1039/c7mt00074j · Cited by 111
Hammond, T. C., Xing, X., Wang, C., Ma, D., Nho, K., Crane, P. K., Elahi, F., Ziegler, D. A., Liang, G., Cheng, Q., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1079-x · Cited by 106
Gandini, A., Bartolini, M., Tedesco, D., Martinez-Gonzalez, L., Roca, C., Campillo, N. E., Zaldivar-Diez, J., Perez, C., Zuccheri, G., Miti, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00610 · Cited by 107
The costs of developing treatments for Alzheimer's disease: A retrospective exploration
Cummings, J. L., Goldman, D. P., Simmons‐Stern, N. R., & Ponton, E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12450 · Cited by 112
Self-citationPrati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110
Precision pharmacology for Alzheimer’s disease
Hampel, H., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J., Dubois, B., Federoff, H. J., Fiandaca, M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 108
“a holistic understanding for the true basis and unique evolution of LOAD, therapeutic interventions based on fAD and transgenic animal model findings provided no significant evidence of clinical efficacy when tested in LOAD individuals [54].”
BackgroundSelf-citationYeung, A. W. K., Tzvetkov, N. T., Georgieva, M. G., Ognyanov, I. V., Kordos, K., Jóźwik, A., Kühl, T., Perry, G., Petralia, M. C., Mazzon, E., et al. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7952 · Cited by 110
“The drug development for NDs had a high failure rate: for example, the failure rate of AD drugs under development during 2002– 2012 was 99.6% (15).”
InfluentialDubois, B., López-Arrieta, J., Lipschitz, S., Doskas, T., Spiru, L., Moroz, S., Venger, O., Vermersch, P., Moussy, A., Mansfield, C. D., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01169-x · Cited by 107
Slowing the progression of Alzheimer’s disease; what works?
Nelson, L., & Tabet, N. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.07.002 · Cited by 109
“Disease-modifying drug treatments remain evasive, and AD has one of the lowest success rates for drug approval into Phase three testing (Cummings et al. 2014).”
Advances in the prevention of Alzheimer's Disease
Sindi, S., Mangialasche, F., & Kivipelto, M. (2015) · F1000Prime Reports · doi:10.12703/p7-50 · Cited by 109
Alzheimer's drug‐development pipeline: 2016
Cummings, J., Morstorf, T., & Lee, G. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.07.001 · Cited by 108
Self-citationSilva, J., Monge‐Fuentes, V., Gomes, F. M. M., Lopes, K. S., dos Anjos, L. C., Campos, G. A. A., Arenas, C., Mayer, A. B., Gonçalves, J. C., Galante, P., et al. (2015) · Toxins · doi:10.3390/toxins7083179 · Cited by 124
Drug repositioning for Alzheimer’s disease based on systematic “omics” data mining
Zhang, M., Schmitt-Ulms, G., Sato, C., Xi, Z., Zhang, Y., Zhou, Y., St George-Hyslop, P., & Rogaeva, E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168812 · Cited by 108
How drug repurposing can advance drug discovery: challenges and opportunities
Pinzi, L., Bisi, N., & Rastelli, G. (2024) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2024.1460100 · Cited by 135
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
